Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostaglandin E2 augments IL-10 signaling and function.

Hyeonjoo Cheon1, Young Hee Rho, Seong Jae Choi

  • 1Department of Pathology, College of Medicine, Korea University, 126-1, Anam-Dong 5-Ga, Sungbuk-Gu, Seoul 136-705, Korea.

Journal of Immunology (Baltimore, Md. : 1950)
|July 5, 2006
PubMed
Summary

Prostaglandin E2 (PGE2) selectively modulates cytokine signaling in rheumatoid arthritis by altering Jak-STAT pathways. This affects immune responses through cAMP signaling and gene expression, potentially via EP2/EP4 receptors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Efficacy and Safety of Telitacicept vs. Belimumab in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Pharmacology·2026
Same author

Long-term Safety and Efficacy of Anifrolumab in Systemic Lupus Erythematosus: A Meta-Analysis of Randomized Controlled Trials, Extension Studies, and Real-World Cohorts.

Pharmacology·2026
Same author

Risk of disease flare and clinical reversibility following discontinuation versus dose reduction of biological DMARDs in Rheumatoid arthritis: A systematic review and meta-analysis.

Seminars in arthritis and rheumatism·2026
Same author

Efficacy and Safety of Janus Kinase Inhibitors in Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same author

Tocilizumab Biosimilars versus Reference Tocilizumab in Rheumatoid Arthritis: A Meta-Analysis of Pharmacokinetic Biosimilarity, Efficacy, Safety, and Immunogenicity.

Pharmacology·2026
Same author

Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence.

Seminars in arthritis and rheumatism·2026

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) involves inflamed joints with high prostaglandin E2 (PGE2) and abundant cytokines like IL-10 and IL-6.
  • PGE2 activates cAMP signaling, which functionally interacts with the Jak-STAT signaling pathway.

Purpose of the Study:

  • To evaluate how PGE2 modulates STAT signaling induced by IL-10 and IL-6 in THP-1 cells.
  • To elucidate the underlying mechanisms of PGE2's effects on cytokine signaling.

Main Methods:

  • Western blot analysis for STAT phosphorylation.
  • Real-time PCR for gene expression analysis.
  • Treatment with PGE2, cytokines (IL-10, IL-6), cAMP analogs, receptor agonists/antagonists, and inhibitors.

Related Experiment Videos

Main Results:

  • PGE2 augmented IL-10-induced STAT3/STAT1 phosphorylation and SOCS3/IL-1R antagonist gene expression.
  • PGE2 suppressed IL-6-induced STAT3/STAT1 phosphorylation.
  • These effects were mediated by intracellular cAMP levels, de novo gene expression, and potentially EP2/EP4 receptors.

Conclusions:

  • PGE2 selectively regulates cytokine signaling pathways, impacting immune responses in THP-1 cells.
  • The modulation involves cAMP signaling and gene expression, suggesting a role for EP2/EP4 receptors.